Adagene, Inc. (ADAG)

NASDAQ: ADAG · IEX Real-Time Price · USD
1.35
+0.23 (20.00%)
At close: Dec 9, 2022 4:00 PM
1.33
-0.02 (-1.48%)
After-hours: Dec 9, 2022 4:50 PM EST
20%
Market Cap 48.85M
Revenue (ttm) 10.18M
Net Income (ttm) -73.21M
Shares Out 54.53M
EPS (ttm) -1.83
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 223,132
Open 1.13
Previous Close 1.13
Day's Range 1.13 - 1.45
52-Week Range 0.9 - 9.7
Beta n/a
Analysts Buy
Price Target 16.35 (+1,111.1%)
Earnings Date n/a

About ADAG

Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTL... [Read more]

Industry Biotechnology
IPO Date Feb 9, 2021
Employees 259
Stock Exchange NASDAQ
Ticker Symbol ADAG
Full Company Profile

Financial Performance

In 2021, Adagene's revenue was $10.18 million, an increase of 1,351.71% compared to the previous year's $700,913. Losses were -$73.18 million, 72.6% more than in 2020.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for ADAG stock is "Buy." The 12-month stock price forecast is 16.35, which is an increase of 1,111.11% from the latest price.

Price Target
$16.35
(1,111.11% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Adagene Appoints Cuong Do to Board of Directors and Audit Committee

SAN DIEGO and SUZHOU, China, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced ...

2 weeks ago - GlobeNewsWire

Adagene Announces Clinical Data at SITC 2022 on Anti-CTLA-4 NEObody™, ADG116, Showing Differentiated Safety and Anti-...

- Interim phase 1b/2 data report safety profile of ADG116 across dosing levels, with repeat dosing of more than four cycles both as monotherapy and in combination with anti-PD-1 therapy -

4 weeks ago - GlobeNewsWire

Adagene Announces Poster Presentations on Anti-CTLA-4 NEObody™, ADG116, at Upcoming Society for Immunotherapy of Canc...

- NEObody technology platform enables dynamic targeting of a distinct epitope of CTLA-4 for enhanced safety and efficacy -

1 month ago - GlobeNewsWire

Adagene Presents Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-Tumor Activity and Pharmacokin...

- Best-in-class profile demonstrated with repeat dosing across dose levels -

2 months ago - GlobeNewsWire

Adagene Reports Financial Results for the Six Months Ended June 30, 2022 and Provides Corporate Updates

– Topline data for anti-CTLA-4 antibody, ADG116, shows compelling clinical safety and complete and partial responses as both a single agent and in combination with anti-PD-1 therapy; results to be prese...

3 months ago - GlobeNewsWire

Adagene Announces Authorization of Share Repurchase Program up to US$10 Million

SAN DIEGO and SUZHOU, China, June 29, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today anno...

5 months ago - GlobeNewsWire

Adagene Announces Publication at ASCO of Interim Monotherapy Dose Escalation Data Showing Compelling Safety Profile o...

- First clinical data demonstrating potential of SAFEbody technology platform to create best-in-class therapeutics -

6 months ago - GlobeNewsWire

Adagene to Participate in Investor Conferences in May and June

SAN DIEGO and SUZHOU, China, May 12, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today annou...

6 months ago - GlobeNewsWire

Adagene Presents Data Demonstrating First and Best-in-Class Potential for Differentiated Preclinical Antibody Candida...

- Poster presentations showcase SAFEbody® precision masking technology applicability across targets and modalities –

8 months ago - GlobeNewsWire

Adagene Reports Full Year 2021 Financial Results and Provides Corporate Update

- 2022 clinical data readouts on track to show potential best-in-class safety profile for anti-CTLA-4 programs (ADG116, ADG126) with PD-1 for proven and new indications, thereby enabling greater efficac...

8 months ago - GlobeNewsWire

Adagene (ADAG) Gets FDA Nod for Cancer Study on ADG126 Combo

The FDA grants clearance to Adagene (ADAG) to begin clinical studies on its anti-CTLA-4 mAb, ADG126 in combination with pembrolizumab to treat advanced/metastatic solid tumors.

8 months ago - Zacks Investment Research

Adagene Shares Pop After FDA Clears Phase 1b/2 Trial For ADG126/Keytruda Combo Therapy In Solid Tumors

The FDA has cleared Adagene Inc's (NASDAQ: ADAG) Phase 1b/2 clinical trial of its anti-CTLA-4 monoclonal antibody (mAb), ADG126, in combination with Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab)...

8 months ago - Benzinga

Adagene Announces FDA Clearance to Proceed with Phase 1b/2 Trial of Anti-CTLA-4 ADG126 SAFEbody® in Combination Thera...

– ADG126-P001 trial being initiated at multiple sites in U.S. and Asia Pacific –

8 months ago - GlobeNewsWire

Investors Hoping for News at Cancer Meeting That Will Boost Share Prices

Given that developing biotechnology companies are more susceptible to swings in stock price than established ones, investors might want to keep an eye on happenings at next month's American Association ...

Other symbols: AMGNGRTSLLY
8 months ago - GuruFocus

Adagene Announces Four Poster Presentations on Robust Preclinical Pipeline of Antibody-Based Therapeutics at Upcoming...

- New IND-enabling programs reinforce commitment to build a deep, broad and differentiated pipeline that transforms cancer immunotherapy leveraging company's AI-powered platform -

9 months ago - GlobeNewsWire

Sanofi Taps Adagene's 'Masking' Tech In Over $2.5B Immuno-Oncology Pact

Sanofi SA (NASDAQ: SNY) has signed a collaboration with Adagene Inc (NASDAQ: ADAG) to advance two preclinical immuno-oncology candidates and an option to develop two more.  Sanofi is paying $17.5 millio...

Other symbols: SNY
9 months ago - Benzinga

Sanofi to pay up to $2.5 billion in deal with Adagene

Shares of Adagene Inc. ADAG, +1.10% jumped 11.2% in premarket trading on Wednesday after it announced a licensing and commercialization deal with Sanofi SNY, -2.65% that is worth up to $2.5 billion. U.S...

Other symbols: SNY
9 months ago - Market Watch

Adagene Announces SAFEbody® Multi-Target Collaboration with Sanofi for Novel Masked Immuno-Oncology Antibody Candidates

- Total potential transaction value of $2.5 billion plus royalties -

9 months ago - GlobeNewsWire

Adagene to Participate in the SVB Leerink 11th Annual Global Healthcare Conference

SAN DIEGO and SUZHOU, China, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today anno...

10 months ago - GlobeNewsWire

Adagene Announces Board and Management Appointments to Support Pipeline Growth

SAN DIEGO and SUZHOU, China, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced ...

10 months ago - GlobeNewsWire

Adagene Announces First Patient Dosed with Novel, Proprietary Combination of Anti-CD137 Agonist, ADG106, and Anti-CTL...

SAN DIEGO and SUZHOU, China, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today anno...

10 months ago - GlobeNewsWire

Adagene Expands Scientific and Strategic Advisory Board with Appointment of David Gandara, M.D.

- Dr. Gandara, Professor and Senior Advisor to the Thoracic Oncology Program at University of California Davis, brings deep expertise and strategic vision in cancer drug and biomarker development-

10 months ago - GlobeNewsWire

Adagene Announces First Patients with Advanced Non-Small Cell Lung Cancer Dosed in Phase 1b/2 Clinical Trial of ADG10...

Clinical trial to be conducted at the National University Cancer Institute, Singapore and the National Cancer Centre Singapore, in Collaboration with the Singapore Translational Cancer Consortium Clinic...

10 months ago - GlobeNewsWire

Adagene Achieves Key Milestone in Collaboration with Exelixis for SAFEbody® Novel Masked Antibody-Drug Conjugate Cand...

- Successful nomination of lead SAFEbody candidates triggers milestone payment -

11 months ago - GlobeNewsWire

Adagene Presents Preclinical Data Showcasing Best-in-Class Profiles for ADG153, an Anti-CD47 SAFEbody® and ADG152, a ...

- Posters presented at the 63 rd American Society of Hematology Annual Meeting -

11 months ago - GlobeNewsWire